Intervention with Therapeutic Agents, Understanding the Path to Remission to Type 2 Diabetes: Part 2.

ABSTRACT: Type 2 diabetes is characterized by progressive decline in pancreatic β-cell function. Newer agents, such as glucagon-like peptide-1 receptor agonist (GLP-1RA) and dual incretin agonists, can augment β-cell function and delay the need for additional antihyperglycemics. However, the effect on β-cell function ceases after stopping the medications. When combined with intensive lifestyle modifications, higher doses of GLP-1RA than those used for diabetes treatment can be used to induce weight loss. More research is needed on whether the weight loss achieved with GLP1-RA can be sustained after stopping medication and in turn can sustain diabetes remission.

SUBMITTER: Hao S 

PROVIDER: S-EPMC10158502 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature